Interleukin-3 amplifies acute inflammation and is a potential therapeutic target in sepsis

  • Georg F Weber
  • Benjamin G Chousterman
  • Shun He
  • Ashley M Fenn
  • Manfred Nairz
  • Atsushi Anzai
  • Thorsten Brenner
  • Florian Uhle
  • Yoshiko Iwamoto
  • Clinton S Robbins
  • Lorette Noiret
  • Sarah L Maier
  • Tina Zönnchen
  • Nuh N Rahbari
  • Sebastian Schölch
  • Anne Klotzsche-von Ameln
  • Triantafyllos Chavakis
  • Jürgen Weitz
  • Stefan Hofer
  • Markus A Weigand
  • Matthias Nahrendorf
  • Ralph Weissleder
  • Filip K Swirski

Abstract

Sepsis is a frequently fatal condition characterized by an uncontrolled and harmful host reaction to microbial infection. Despite the prevalence and severity of sepsis, we lack a fundamental grasp of its pathophysiology. Here we report that the cytokine interleukin-3 (IL-3) potentiates inflammation in sepsis. Using a mouse model of abdominal sepsis, we showed that innate response activator B cells produce IL-3, which induces myelopoiesis of Ly-6C(high) monocytes and neutrophils and fuels a cytokine storm. IL-3 deficiency protects mice against sepsis. In humans with sepsis, high plasma IL-3 levels are associated with high mortality even after adjusting for prognostic indicators. This study deepens our understanding of immune activation, identifies IL-3 as an orchestrator of emergency myelopoiesis, and reveals a new therapeutic target for treating sepsis.

Bibliographical data

Original languageEnglish
ISSN0036-8075
DOIs
Publication statusPublished - 13.03.2015
Externally publishedYes
PubMed 25766237